Daiichi Sankyo Europe announced the enrolment of the first patient into the PREFER in VTE (Prevention of thromboembolic events – European registry in venous thromboembolism) study on 6 February 2013. PREFER in VTE is the first patient registry to gather comprehensive data on the quality of life and treatment satisfaction of patients with venous thromboembolism (VTE). It will also provide detailed insights into the process of patient management in the acute treatment phase, as well as in the prevention of repeat thromboembolic events. In addition, the PREFER in VTE registry will investigate the economic burden of venous thromboembolism treatment.
Discussing the importance of this registry, Alexander T Cohen, honorary consultant Vascular Medicine, Department of Vascular Surgery, King’s College Hospital, London, UK, said, “The enrolment of the first patient in this registry is an exciting milestone. PREFER in VTE is the first registry of its kind that will provide detailed insight into the patient’s perspective. Relying on patient interviews and diaries rather than focusing purely on a doctor’s assessment of venous thromboembolism, will give us important patient data outside of a clinical trial setting.”
The PREFER in VTE registry plans to enrol more than 4,000 patients with venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) across approximately 400 recruiting hospitals and specialised centres, in seven European countries (Austria, France, Germany, Italy, Spain, Switzerland and the UK). By collecting key data from different geographies, the registry will highlight important risk factors, as well as demonstrate diagnosis pathways and treatment modalities in this patient population. The review of current therapy and healthcare resource use will allow an evaluation of the relationship between the use of anticoagulants and approximate therapy costs. In contrast to other registries in this setting, PREFER in VTE is the first of its kind to also analyse the relationship between venous thromboembolism treatment, a patient’s quality of life and treatment satisfaction.
In 2012, Daiichi Sankyo Europe started another large registry, focussing on patients suffering from atrial fibrillation (AF) – the Prevention of thromboembolic events – European registry in atrial fibrillation (PREFER in AF). The company has now completed the enrolment of more than 7,100 patients who will be followed up for 12 months. The first set of data will be available in the summer of 2013.
Daiichi Sankyo discovered and is currently studying edoxaban, a novel once-daily oral factor Xa inhibitor, as a potential new treatment option for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation. It is also being developed for the potential treatment and prevention of recurrence of venous thromboembolism in patients with deep vein thrombosis and/or pulmonary embolism.
